Lamivudine
- Product NDC
- 64380-711
- 11-digit product format
- 643800711
- Labeler code
- 64380
- Product ID
- 64380-711_904931df-ec36-416c-aedd-6a09b1137b57
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Lamivudine
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- Strides Pharma Science Limited
- Application
- ANDA090457
- Marketing category
- ANDA
- Marketing start
- 2018-10-19
- Substance
- LAMIVUDINE
- Active strength
- 300 mg/1
- Pharmacologic classes
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Reverse Transcriptase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Lamivudine
- Listing expiration
- 2027-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| LAMIVUDINE | 300 mg/1 |
Harmonized Identifiers#
Field, Values table| Field | Values |
|---|
| Unii | 2T8Q726O95 |
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
NDC, Effective, Action table| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|
| 64380-711-04 | 2025-02-24 | C162847 | 48780-1 | 2cef2736-8b2c-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use LAMIVUDINE TABLETS, safely and effectively. See full prescribing information for LAMIVUDINE TABLETS. LAMIVUDINE tablets, for oral use Initial U.S. Approval: 1995 |
| 64380-711-04 | 2025-02-24 | C162847 | 48780-1 | 2cef2736-8b2c-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use LAMIVUDINE TABLETS, safely and effectively. See full prescribing information for LAMIVUDINE TABLETS. LAMIVUDINE tablets, for oral use Initial U.S. Approval: 1995 |
| 64380-711-04 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-8b2c-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use LAMIVUDINE TABLETS, safely and effectively. See full prescribing information for LAMIVUDINE TABLETS. LAMIVUDINE tablets, for oral use Initial U.S. Approval: 1995 |
| 64380-711-04 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-8b2c-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use LAMIVUDINE TABLETS, safely and effectively. See full prescribing information for LAMIVUDINE TABLETS. LAMIVUDINE tablets, for oral use Initial U.S. Approval: 1995 |
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 64380-711-04 | Lamivudine | 30 in 1 BOTTLE | TABLET, FILM COATED | 30 | | 7 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 64380-711 | LAMIVUDINE TABLET, FILM COATED [STRIDES PHARMA SCIENCE LIMITED] | 7 | Current NDC, Legacy NDC, 1 package rows | 20250330_ac824c7e-9c9f-487b-ad2f-d50eaef5cbda.zip |
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 64380-711-04 | 64380071104 | 30 TABLET, FILM COATED in 1 BOTTLE (64380-711-04) | 2018-10-19 | 0000-00-00 | No | No | Current |